Loading chat...

TN SB1848

Bill

Official Source

Status

Introduced

1/21/2026

Primary Sponsor

Becky Massey

Click for details

Origin

Senate

114th General Assembly

AI Summary

  • Authorizes healthcare providers to directly administer buprenorphine mono-products (without naloxone) on-site for substance use disorder treatment under a physician's order
  • Prohibits dispensing buprenorphine mono-products in a manner that allows patients to take the medication off-premises for self-administration
  • Restricts prescribing or dispensing of buprenorphine without naloxone to specific exceptions: pregnant women, nursing mothers, patients with documented adverse reactions or hypersensitivity, and injectable mono-products
  • Takes effect immediately upon becoming law

Legislative Description

AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to the use of buprenorphine products.

Controlled Substances

Last Action

Placed on Senate Health and Welfare Committee calendar for 3/17/2026

3/11/2026

Committee Referrals

Health and Welfare2/2/2026

Full Bill Text

No bill text available